This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The incidence of medication errors varies greatly among published studies, not only due to the lack of a clear definition, 1,2 but also because of different factors such as the healthcare setting, differing levels of automation (e.g. 3–5 Medication errors are often documented in national or local electronic incident reporting systems.
Many patients will not experience a therapeutic effect at standard dosages, whereas others might be more susceptible to adverse effects or toxicity. If these results can be integrated into a patient’s medicalrecords, they can be used to inform the prescription of future medicines throughout that patient’s life.
However, it can be challenging for patients to stick to their prescribed therapy, especially when they have co-morbid conditions requiring multiple medications or when they are more likely to forget their treatment regimen due to underlying issues, such as mental health conditions. By 2034, this number is expected to soar to $1.8
GlobalData forecasts that the market for AI platforms for the entire healthcare industry will reach $4.3bn by 2024, up from $1.5bn in 2019 [i]. For a detailed analysis and valuable insights into deploying successful NMT programs, download the paper below. [i]
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content